DE69318415D1 - Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen - Google Patents

Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen

Info

Publication number
DE69318415D1
DE69318415D1 DE69318415T DE69318415T DE69318415D1 DE 69318415 D1 DE69318415 D1 DE 69318415D1 DE 69318415 T DE69318415 T DE 69318415T DE 69318415 T DE69318415 T DE 69318415T DE 69318415 D1 DE69318415 D1 DE 69318415D1
Authority
DE
Germany
Prior art keywords
layer
pct
release
active substances
different disposal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69318415T
Other languages
English (en)
Other versions
DE69318415T2 (de
Inventor
Ubaldo Conte
Manna Aldo La
Lauretta Maggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11363994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69318415(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of DE69318415D1 publication Critical patent/DE69318415D1/de
Publication of DE69318415T2 publication Critical patent/DE69318415T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69318415T 1992-09-24 1993-09-21 Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen Revoked DE69318415T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI922192A IT1255522B (it) 1992-09-24 1992-09-24 Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
PCT/EP1993/002556 WO1994006416A1 (en) 1992-09-24 1993-09-21 Pharmaceutical tablet capable of liberating one or more drugs at different release rates

Publications (2)

Publication Number Publication Date
DE69318415D1 true DE69318415D1 (de) 1998-06-10
DE69318415T2 DE69318415T2 (de) 1998-09-03

Family

ID=11363994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69318415T Revoked DE69318415T2 (de) 1992-09-24 1993-09-21 Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen

Country Status (12)

Country Link
US (1) US5738874A (de)
EP (1) EP0663820B1 (de)
JP (2) JP3811499B2 (de)
AT (1) ATE165734T1 (de)
AU (1) AU675663B2 (de)
CA (1) CA2145513C (de)
DE (1) DE69318415T2 (de)
DK (1) DK0663820T3 (de)
ES (1) ES2117146T3 (de)
IT (1) IT1255522B (de)
NZ (1) NZ256020A (de)
WO (1) WO1994006416A1 (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
AU5123396A (en) * 1995-04-03 1996-10-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing sucralfate
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
IT1276689B1 (it) * 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
IT1295271B1 (it) * 1997-10-03 1999-05-04 Chiesi Farma Spa Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
EP0956858B1 (de) * 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
JP2010024239A (ja) * 1998-05-06 2010-02-04 Kowa Co 消化管運動抑制剤
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
WO2000015197A1 (en) * 1998-09-14 2000-03-23 Rubin Alan A Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
EP1115379A2 (de) * 1998-09-25 2001-07-18 Delsys Pharmaceutical Corporation Flüssiges pharmazeutikum zur oralen verabreichung
WO2000045734A1 (en) 1999-02-02 2000-08-10 Wright Medical Technology, Inc. Controlled release composite
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
MXPA01010377A (es) * 1999-04-13 2002-10-23 Beecham Pharm Pte Ltd Metodo novedoso de tratamiento.
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
IL150568A0 (en) 2000-02-04 2003-02-12 Depomed Inc A controlled release oral drug dosage form
US6458384B2 (en) 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
WO2001062195A1 (en) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (de) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Amoxicillinhaltige arzneizusammensetzungen
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
DE60212475T2 (de) * 2001-03-14 2007-07-05 Pfizer Products Inc., Groton Pharmazeutische Tablette und ein Verfahren zu ihrer Herstellung
US20030143272A1 (en) * 2001-03-14 2003-07-31 Waterman Kenneth C. Pharmaceutical tablet and process for making thereof
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
CN1596101A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
ITMI20020514A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US6902746B2 (en) * 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
BR0313745A (pt) * 2002-08-23 2005-07-12 Ranbaxy Lab Ltd Apresentação farmacêutica de liberação controlada de nitrofurantoina e processo para sua preparação
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
JP2006500395A (ja) * 2002-09-09 2006-01-05 エンド ファーマシューティカルズ インコーポレーテッド 組み合わされた即時放出及び徐放の鎮痛組成物
EP1537880A4 (de) * 2002-09-11 2009-07-01 Takeda Pharmaceutical PRûPARAT MIT VERZ GERTER FREISETZUNG
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
CA2499882C (en) * 2002-09-28 2010-11-09 Mcneil-Ppc, Inc. Modified release dosage form with two cores
AU2003282603A1 (en) * 2002-10-11 2004-05-04 Depomed Development Ltd Gastro-retentive levodopa delivery form
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
FR2855756B1 (fr) * 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
MXPA05013202A (es) 2003-06-06 2006-03-09 Ethypharm Sa Tableta de multiples capas oralmente dispersable.
AU2007202920B2 (en) * 2003-06-19 2009-10-29 Aristocrat Technologies Australia Pty Limited A gaming system with a cashier terminal
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
PL1591109T3 (pl) * 2004-04-30 2008-11-28 Topotarget Germany Ag Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”
WO2005112898A1 (en) 2004-05-21 2005-12-01 Accu-Break Pharmaceuticals, Inc. Pharmaceutical tablets having a relatively inactive segment
TWI428271B (zh) * 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
AU2007202381C1 (en) * 2004-06-18 2010-03-11 Aristocrat Technologies Australia Pty Ltd Cashless reservation system
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
JP4681843B2 (ja) * 2004-09-30 2011-05-11 日本臓器製薬株式会社 固形医薬製剤
BRPI0518125A (pt) 2004-11-19 2008-10-28 Smithkline Beecham Corp produto farmacêutico
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
CA2587514A1 (en) * 2004-12-03 2006-06-08 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
JP5259413B2 (ja) * 2005-11-18 2013-08-07 エーシーシーユー−ブレイク テクノロジーズ，インク． セグメント化した薬の剤形
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
DE602006018529D1 (de) * 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
DE102006058252A1 (de) * 2006-12-08 2008-06-12 Aris Handels Gmbh Vorrichtung zur Insektenbekämpfung, insbesondere zur Bekämpfung von Fliegen
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
JP5823093B2 (ja) * 2006-03-28 2015-11-25 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2029116A4 (de) * 2006-06-19 2012-07-04 Accu Break Technologies Inc Segmentierte pharmazeutische dosierungsformen
WO2008070268A2 (en) * 2006-10-09 2008-06-12 Charleston Laboratories, Inc. Pharmaceutical compositions
SI2124556T1 (sl) * 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
KR20140088619A (ko) * 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) * 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
JP2010511627A (ja) * 2006-11-30 2010-04-15 エーシーシーユー−ブレイク テクノロジーズ，インク． 分割可能な浸透性剤形及びその使用方法
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2217213B1 (de) 2007-10-31 2017-05-24 Johnson & Johnson Consumer Inc. Im mund zerfallende dosierform
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
EP3090743A1 (de) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
CA2733787C (en) * 2008-08-15 2016-09-06 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8313768B2 (en) * 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
KR101841442B1 (ko) * 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
AU2011236548A1 (en) * 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
IT1406328B1 (it) * 2010-12-23 2014-02-21 S I I T S R L Ora S I I T S R L Unipersonale Compressa multistrato a rilascio diversificato
US9029401B2 (en) 2011-02-14 2015-05-12 The Regents Of The University Of California Sorafenib derivatives as sEH inhibitors
EP2508174A1 (de) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmazeutische Zusammensetzung
EP3453711B1 (de) 2011-09-02 2021-08-18 The Regents of the University of California Llp2a-bisphosphonat-konjugate zur behandlung von osteoporose
EP2809650B1 (de) 2012-02-01 2018-04-11 The Regents of The University of California Acylpiperidinderivate als inhibitoren der löslichen epoxidhydrolase
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
ITMI20121263A1 (it) 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica multistrato
CN113416187B (zh) 2013-03-14 2024-07-19 奥斯菲治疗有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
EP3054929B1 (de) 2013-10-07 2020-08-05 Impax Laboratories, LLC Mukoadhäsive levodopa-formulierungen mit gesteuerter freisetzung und/oder levodopa-ester und verwendungen davon
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN106068120B (zh) 2014-01-10 2021-03-23 强生消费者公司 使用射频和有损耗的包衣粒子制造片剂的方法
EP2937096B1 (de) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2017176652A2 (en) * 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
JP2022504011A (ja) 2018-08-14 2022-01-13 オステオーク インコーポレイティド ピロロ－ジピリジン化合物
JP2021535091A (ja) 2018-08-14 2021-12-16 オステオーク インコーポレイティド フルオロβ−カルボリン化合物
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022171A (en) * 1961-06-15 1966-03-09 Wellcome Found Prolonged release oral pharmaceutical tablets and their manufacture
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
IT1196190B (it) * 1984-07-12 1988-11-10 Lisapharma Spa Forma farmaceutica solida orale ad azione sequenziale per la somministrazione di farmaci ad effetto collaterale ulcerogeno
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive

Also Published As

Publication number Publication date
EP0663820B1 (de) 1998-05-06
DE69318415T2 (de) 1998-09-03
ITMI922192A0 (it) 1992-09-24
AU4818293A (en) 1994-04-12
IT1255522B (it) 1995-11-09
ITMI922192A1 (it) 1994-03-24
EP0663820A1 (de) 1995-07-26
CA2145513A1 (en) 1994-03-31
JPH08501544A (ja) 1996-02-20
NZ256020A (en) 1996-09-25
JP3811499B2 (ja) 2006-08-23
CA2145513C (en) 1999-12-07
ES2117146T3 (es) 1998-08-01
JP2006160762A (ja) 2006-06-22
US5738874A (en) 1998-04-14
AU675663B2 (en) 1997-02-13
DK0663820T3 (da) 1999-03-01
ATE165734T1 (de) 1998-05-15
WO1994006416A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
DE69318415D1 (de) Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
GR1002564B (el) Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως.
GR3015731T3 (en) Use of interfacially-polymerized membranes in delivery devices.
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
SE9500422D0 (sv) New oral pharmaceutical dosage forms
MY112915A (en) Multiple unit tableted dosage form 1
DK0841903T3 (da) Orale farmaceutiske præparater indeholdende antimikrobielt virksomme aktivstoffer og sustained release pantoprazol
DK0494972T3 (da) Brusedosisform samt fremgangsmåde til administration heraf
DE69405752D1 (de) Filmbeschichtete tablette von astemizol und pseudoephedrin mit verlängerter freigabe
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
ES2161690T3 (es) Formulaciones farmaceuticas.
CA2116238A1 (en) Oral 1 .alpha.-hydroxyprevitamin d
DK0577504T3 (da) Niacin-holdige sustained release-tabletter og -kits
DE69817587D1 (de) Aus einer vielzahl von kleineinheiten aufgebaute brausedosisform
ATE103174T1 (de) Arzneimittel mit verzoegerter wirkstofffreigabe.
EP0235718A3 (en) Granule remaining in stomach
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
CA2101697A1 (en) Controlled release potassium chloride tablet
FR2718020B1 (fr) Composition galénique mucoadhésive hétérofonctionnelle.
ATE290854T1 (de) Carbamazepinformulierung mit verzögerter freigabe
GB9814215D0 (en) Anti-inflammatory pharmaceutical formulations
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
GR3024854T3 (en) Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances.
ATE207756T1 (de) Pharmazeutische zusammensetzung, die muirapuama und pflanzenwürmer enthaelt

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation